Health-care companies claim they are not threatened by Amazon's potential foray into the space. A recent lawsuit suggests otherwise.Technologyread more
It wasn't supposed to be this way: The 2017 tax cut and aggressive moves toward deregulation were supposed to pull the U.S. economy out of its glacial move higher.Economyread more
The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday.Bondsread more
Slack pursued an unusual direct listing, meaning it did not have banks underwrite the offering.CNBC Disruptor 50read more
President Trump says Iran may not have intentionally downed an unmanned U.S. surveillance drone.Politicsread more
Slack's public market debut on Thursday will generate billions for venture firm Accel and healthy returns for Andreessen Horowitz and Social Capital.Technologyread more
The road to the Fed's policy pivot to lower interest rates began in early May, with a tweet from President Trump on trade.Market Insiderread more
See which stocks are posting big moves after the bell on June 20.Market Insiderread more
Chairman Jerry Nadler, D-N.Y., said in a statement that lawyers for the Trump administration blocked Hicks from answering questions 155 times during the Wednesday hearing.Politicsread more
Jim Cramer says "you'll want to keep some powder dry so you can buy into weakness and get some real bargains."Mad Money with Jim Cramerread more
CNBC analysis using Kensho found that Disney, Verizon and Home Depot were some of the best performing Dow stocks in declining-rate environments.Investingread more
Swiss pharmaceutical giant Roche Group is buying Flatiron Health, an Alphabet-backed cancer-focused start-up founded by two former Google employees, according to sources familiar with the matter. The company will pay $1.9 billion, adding to its existing stake, for a total value of $2.1 billion.
The company has confirmed the deal in a press release.
Flatiron was valued at $1.2 billion when it raised its last round from Roche in 2016. Medical distribution giant McKesson was also interested in buying the company, sources say.
Alongside Alphabet's GV (formerly Google Ventures), Roche is one of the biggest backers in Flatiron, having led the most recent venture round of $175 million in 2016. It already owned 12% of the company. As part of the deal, Roche agreed to acquire several of the company's software products, which was intended to put the company in a position to go public.
Flatiron has an electronic medical record system used by doctors who are treating patients with cancer. It then uses this data to help researchers and life sciences companies figure out better treatments for cancer -- for instance, by making sure that the right patients are being recruited for clinical trials.
The company was founded by former Google employees Nat Turner and Zach Weinberg.
Flatiron's founders told the New York Times in 2016 that it planned to go public in two to three years. Prior to being sold, Flatiron had intended to raise an additional round of financing.
In a conversation with CNBC, CEO Nat Turner said the company will remain an independent legal entity "within the Roche family of companies." Turner said that was a requirement for Flatiron as it sought out interest in a potential deal. The employees, including the founding team, will stay on as Flatiron employees, he added.
"Nothing is changing from the brand identity perspective," he said.
Flatiron has raised more than $300 million from investors across the technology and health care investors, including Roche, Allen & Company, GV, First Round Capital and SV Angel.
The transaction is expected to close in the first half of this year and will bolster Roche's oncology portfolio. Roche has ramped up its interest in companies at the intersection of medicine and technology, through partnerships with 23andMe, Foundation Medicine as well as the strategic investment in Flatiron.